2 weeks Ago By Defense World Staff
Prudential Financial Inc. bought a new position in Spero Therapeutics, Inc. ( NASDAQ:SPRO – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).
The institutional investor bought 49,200 shares of the company’s stock, valued at approximately $51,000. Prudential Financial Inc. owned approximately 0.
09% of Spero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Separately, Virtu Financial LLC purchased a new position in Spero Therapeutics in the 4th quarter worth approximately $47,000. 25.
60% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In A number of research firms have commented on SPRO. Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.
00 target price for the company. in a report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $5.
00 price objective on shares of Spero Therapeutics in a report on Thursday, January 30th. Spero Therapeutics Trading Up 3.9 % Shares of SPRO stock opened at $0.
60 on Friday. Spero Therapeutics, Inc. has a 12-month low of $0.
51 and a 12-month high of $1.72. The stock has a market capitalization of $33.
54 million, a P/E ratio of 8.57 and a beta of 0.64.
The firm’s 50 day moving average is $0.76 and its 200 day moving average is $0.99.
Spero Therapeutics ( NASDAQ:SPRO – Get Free Report ) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.
35) by ($0.03). The firm had revenue of $15.
04 million during the quarter, compared to analysts’ expectations of $12.40 million. Spero Therapeutics had a return on equity of 4.
03% and a net margin of 3.30%. As a group, equities analysts predict that Spero Therapeutics, Inc.
will post -1.2 earnings per share for the current year. Insider Buying and Selling at Spero Therapeutics In other news, CEO Sath Shukla sold 155,333 shares of the business’s stock in a transaction on Wednesday, February 5th.
The shares were sold at an average price of $0.78, for a total transaction of $121,159.74.
Following the completion of the sale, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. The trade was a 8.
21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link . Also, Director Ankit Mahadevia sold 69,219 shares of the company’s stock in a transaction on Wednesday, February 5th.
The stock was sold at an average price of $0.78, for a total value of $53,990.82.
Following the completion of the sale, the director now owns 689,866 shares of the company’s stock, valued at $538,095.48. This trade represents a 9.
12 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 245,241 shares of company stock worth $191,288 in the last three months.
4.52% of the stock is currently owned by company insiders. Spero Therapeutics Profile ( Free Report ) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. Recommended Stories Five stocks we like better than Spero Therapeutics What is the Australian Securities Exchange (ASX) JPMorgan is a Buy, if You Can Handle The Volatility Dividend Screener: How to Evaluate Dividend Stocks Before Buying United States Steel’s Crash: An Unmissable Buying Opportunity 3 Healthcare Dividend Stocks to Buy Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding SPRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spero Therapeutics, Inc.
( NASDAQ:SPRO – Free Report ). Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
